title: No effect of the CYP1A2*1F genotype on thioridazine, mesoridazine, sulforidazine plasma concentrations in psychiatric patients.
authors.forename: Pedro
authors.initials: P
authors.lastname: Dorado
authors.forename: Roland
authors.initials: R
authors.lastname: Berecz
authors.forename: Eva M
authors.initials: EM
authors.lastname: Peñas-Lledó
authors.forename: Alfredo
authors.initials: A
authors.lastname: de la Rubia
authors.forename: Adrián
authors.initials: A
authors.lastname: Llerena
mesh_terms: D000483:Alleles; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000493:pharmacokinetics*; D019388:Cytochrome P-450 CYP1A2; D003647:Debrisoquin / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D005838:Genotype; D006801:Humans; D001523:Mental Disorders; D008653:Mesoridazine / Q000097:blood*; D010640:Phenothiazines / Q000097:blood*; D016133:Polymerase Chain Reaction; D011110:Polymorphism, Genetic; D012150:Polymorphism, Restriction Fragment Length; D012907:Smoking; D013881:Thioridazine / Q000008:administration & dosage / Q000493:pharmacokinetics*
chemical_list: D014150:Antipsychotic Agents; D010640:Phenothiazines; D008653:Mesoridazine; C040634:sulforidazine; D019388:Cytochrome P-450 CYP1A2; D013881:Thioridazine; D003647:Debrisoquin